Low Prevalence of Human T‐Cell Lymphotropic Virus Type 1 (HTLV‐1) in a Hospital Triage Population in Tehran During 2024–2025
Open Access
- 11 August 2026
- journal article
- research article
- Published by Wiley in Health Science Reports
- Vol. 9 (8) , e73040
Abstract
Background and Aims: Human T‐cell lymphotropic virus type 1 (HTLV‐1) is a retrovirus that is associated to adult T‐cell leukemia/lymphoma (ATLL) and HTLV‐1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) as two major diseases of the virus. Due to limited data on its prevalence in general populations in Tehran and as this virus is endemic in Iran, this study aimed to assess HTLV‐1 prevalence among patients attending the triage unit of Imam Khomeini Hospital during 2024–2025. Methods: In this cross‐sectional study conducted between 2024 and 2025, patients presenting to the triage unit were randomly selected. Exclusion criteria included active infection with HBV, HCV, or HIV, and receiving antiretroviral therapy (ART). After obtaining informed consent, 5 mL of whole blood was collected from each participant. The DNJIA kit (ROJE Technologies, Iran) was used to extract DNA. We used primers that targeted the HBZ and Tax regions of the viral genome to do PCR amplification to find HTLV‐1. Results: Out of 197 individuals enrolled in this cross‐sectional study, 1 participant (0.51%) was positive for HTLV‐1. The HTLV‐1‐positive case was a 40‐year‐old single male with a history of both blood transfusion and prior surgery, but no history of organ transplantation, substance addiction, or travel. Most of the people who took part were men (54.3%) and married (58.9%), and their average age was 39.7 ± 12.1 years. Fisher's exact test showed a statistically significant association between HTLV‐1 positivity and a history of blood transfusion ( p = 0.015) and a significant link with a history of surgery ( p = 0.020). History of blood transfusion, organ transplantation, surgery, and addiction were reported by 3 (1.5%), 1 (0.5%), 4 (2.0%), and 1 (0.5%) participants, respectively. Foreign travel was reported by 77 (39.1%) participants, whereas 100 (50.8%) had a history of domestic travel. The most frequently visited foreign destinations were Turkey ( n = 25) and the United Arab Emirates ( n = 20). Among domestic destinations, the most commonly visited cities were Isfahan ( n = 22) and Mazandaran ( n = 19). Conclusion: The only positive case (0.51%) had known risk factors associated to HTLV‐1 infection including prior surgery and blood transfusion. Given the higher reported prevalence of HTLV‐1 in endemic regions including Iran, and the increased risk among certain populations—such as individuals with a history of intravenous drug use, multiple sexual partners, or co‐infection with other viruses—future studies should focus on these high‐risk groups and the virus prevalence over time. Targeted screening in such populations may provide a more accurate picture of the virus's distribution during different time frames for more effective control and prevention measures.Keywords
This publication has 30 references indexed in Scilit:
- Screening for HTLV-1 infection should be expanded in EuropeInternational Journal of Infectious Diseases, 2024
- Determination of molecular epidemiologic pattern of human T-lymphotropic virus type 1 (HTLV-1) in Alborz province, IranVirus Genes, 2024
- Prevalence of infection by human T Cell lymphotropic viruses (HTLV-1/2) in adult population in Vitória-ESThe Brazilian Journal of Infectious Diseases, 2021
- HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signalingProceedings of the National Academy of Sciences, 2020
- Human T‐lymphotropic virus type 1 infection and solid organ transplantationReviews in Medical Virology, 2018
- The discovery of HTLV-1, the first pathogenic human retrovirusProceedings of the National Academy of Sciences, 2015
- Prevalence and phylogenetic analysis of HTLV‐1 in a segregated population in IranJournal of Medical Virology, 2015
- High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology surveyJournal of Clinical Virology, 2011
- Seroprevalence of HTLV-I and HTLV-II among Intravenous Drug Users and Persons in Clinics for Sexually Transmitted DiseasesNew England Journal of Medicine, 1992
- Prevalence of HTLV-1 Antibodies in Hemodialysis Patients in JapanAmerican Journal of Kidney Diseases, 1988